In silico veritas? Potential limitations for SARS-CoV-2 vaccine development based on T-cell epitope prediction

Sandra Silva-Arrieta; Philip J. R. Goulder; Christian Brander

doi:10.1371/journal.ppat.1008607

Loading metrics

Open Access

Opinion articles provide a forum for expression of views, and responses to previous statements, on a range of topical, emerging and controversial issues.

See all article types »

In silico veritas? Potential limitations for SARS-CoV-2 vaccine development based on T-cell epitope prediction

Sandra Silva-Arrieta,

Affiliation IrsiCaixa AIDS Research Institute, Hospital Germans Trias i Pujol, Institute for Health Science Research Germans Trias i Pujol (IGTP), Badalona, Spain
⨯
Philip J. R. Goulder,

Affiliations Department of Paediatrics, University of Oxford, Oxford, United Kingdom, HIV Pathogenesis Programme, The Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban, South Africa, Ragon Institute of MGH, MIT, and Harvard, Cambridge, Massachusetts, United States of America
⨯
Christian Brander

* E-mail: cbrander@irsicaixa.es

Affiliations IrsiCaixa AIDS Research Institute, Hospital Germans Trias i Pujol, Institute for Health Science Research Germans Trias i Pujol (IGTP), Badalona, Spain, University of Vic–Central University of Catalonia, Catalonia, Vic, Spain, Catalan Institution for Research and Advanced Studies (ICREA), Barcelona, Spain

http://orcid.org/0000-0002-0548-5778

⨯

In silico veritas? Potential limitations for SARS-CoV-2 vaccine development based on T-cell epitope prediction

Sandra Silva-Arrieta,
Philip J. R. Goulder,
Christian Brander

Published: June 4, 2020
https://doi.org/10.1371/journal.ppat.1008607

About the Authors

Sandra Silva-Arrieta

Affiliation IrsiCaixa AIDS Research Institute, Hospital Germans Trias i Pujol, Institute for Health Science Research Germans Trias i Pujol (IGTP), Badalona, Spain

Philip J. R. Goulder

Affiliations Department of Paediatrics, University of Oxford, Oxford, United Kingdom, HIV Pathogenesis Programme, The Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban, South Africa, Ragon Institute of MGH, MIT, and Harvard, Cambridge, Massachusetts, United States of America

Christian Brander

* E-mail: cbrander@irsicaixa.es

Affiliations IrsiCaixa AIDS Research Institute, Hospital Germans Trias i Pujol, Institute for Health Science Research Germans Trias i Pujol (IGTP), Badalona, Spain, University of Vic–Central University of Catalonia, Catalonia, Vic, Spain, Catalan Institution for Research and Advanced Studies (ICREA), Barcelona, Spain

http://orcid.org/0000-0002-0548-5778

Competing Interests

The authors have declared that no competing interests exist.

Subject Areas
?

For more information about PLOS Subject Areas, click here.
We want your feedback. Do these Subject Areas make sense for this article? Click the target next to the incorrect Subject Area and let us know. Thanks for your help!

T cells
Is the Subject Area "T cells" applicable to this article?

Thanks for your feedback.
SARS CoV 2
Is the Subject Area "SARS CoV 2" applicable to this article?

Thanks for your feedback.
COVID 19
Is the Subject Area "COVID 19" applicable to this article?

Thanks for your feedback.
Immune response
Is the Subject Area "Immune response" applicable to this article?

Thanks for your feedback.
Vaccine development
Is the Subject Area "Vaccine development" applicable to this article?

Thanks for your feedback.
Viral vaccines
Is the Subject Area "Viral vaccines" applicable to this article?

Thanks for your feedback.
Antigen-presenting cells
Is the Subject Area "Antigen-presenting cells" applicable to this article?

Thanks for your feedback.
HIV vaccines
Is the Subject Area "HIV vaccines" applicable to this article?

Thanks for your feedback.